A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-06-15) →
What happened
GeneOne Life Science updated the disclosed terms of an acquisition, now worth US$2.02M.
For context, this deal is worth about 2.5% of the company's own total assets.
| Target | Disclosed |
|---|---|
| Deal value | US$2.02M |
| vs. company assets | 2.5% |
| Filed | 2026-04-30, [Amended] Decision to acquire shares/equity in another company |
| Source | DART rcept 20260430801409 → open original filing |
Versions of this filing
- 2026-04-14Original
- 2026-04-30Amendment 1 (this page)
- 2026-05-15Amendment 2
- 2026-06-15Amendment 3
Source: DART. Information only, not investment advice.